Effects of protein restriction on insulin-like growth factor (IGF)-1 in men with prostate cancer: results from a randomized clinical trial

Maria L. Cagigas, Giovanni Fiorito, Beatrice Bertozzi, Andrius Masedunskas, Edda Cava, Francesco Spelta, Nicola Veronese, Valeria Tosti, Gayathiri Rajakumar, Tiana Pelaia, Arnold D. Bullock, Robert S. Figenshau, Gerald L. Andriole, Luigi Fontana

Research output: Contribution to journalLetterpeer-review

Abstract

Background: Insulin-like growth factor (IGF)-1 and its binding proteins are important in cancer growth, especially in prostate cancer. Observational studies suggest that protein restriction can lower IGF-1 levels. However, it is unclear whether an isocaloric protein-restricted diet affects IGF-1 and IGFBPs in men with prostate cancer. Methods: In this academic, single-center, parallel-group, prospective, randomized, open-label, blinded end-point trial, 38 consenting overweight (BMI 30.5 ± 5.5 kg/m2) men with localized prostate cancer, aged 43–72 years, were randomized (1:1) with permuted blocks to 4–6 weeks of customized isocaloric PR diets (0.8 g protein/kg lean body mass) or their usual diet. Biomarkers influencing cancer biology, including serum IGF-1 and its binding proteins were measured longitudinally. Results: Contrary to our hypothesis, feeding individuals an isocaloric protein-restricted diet did not result in a significant reduction in serum IGF-1. Moreover, there was no observed increase in serum IGFBP-1 or IGFBP-3 concentration. Conclusion: These findings demonstrate that protein restriction without calorie restriction does not reduce serum IGF-1 concentration or increase IGFBP-1 and IGFBP-3 in men with localized prostate cancer. Further research is needed to identify dietary interventions for safely and effectively reducing IGF-1 in this patient group.

Original languageEnglish
Article number68
JournalBiomarker Research
Volume12
Issue number1
DOIs
StatePublished - Dec 2024

Fingerprint

Dive into the research topics of 'Effects of protein restriction on insulin-like growth factor (IGF)-1 in men with prostate cancer: results from a randomized clinical trial'. Together they form a unique fingerprint.

Cite this